3hp-2827
Solid Tumors With FGFR2 Alterations, Adult
3H (Suzhou) Pharmaceuticals Co., Ltd.Phase 1/2Active
CCC
54/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 40/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Solid Tumors With FGFR2 Alterations, Adult cohort.
| Asset / Sponsor | Phase | Rating |
|---|
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →